Lantheus Medical Imaging parent company Lantheus Holdings and partner Point Biopharma Global have secured fast-track designation from the U.S. Food and Drug Administration (FDA) for lutetium-177 (Lu-177) PNT2002, a radiopharmaceutical for the treatment of metastatic, castration-resistant prostate cancer.
Lantheus licensed exclusive marketing rights for the agent from Point Biopharma Global in December of last year, it said.
